Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (3.700.187 €): VPH-Kardiovaskuläre Simulation und Experimente für personalisierte Medizinprodukte Hor01.01.2015 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
VPH-Kardiovaskuläre Simulation und Experimente für personalisierte Medizinprodukte
VPH-CaSE is focused on state-of-the-art developments in personalised cardiovascular support, underpinned by simulation and experimentation, building on the foundations of the Virtual Physiological Human (VPH) Initiative. The Individual Research Projects of 14 ESRs provide knowledge exchange across three research clusters (i) Cardiac tissue function and cardiac support (ii) Cardiovascular haemodynamics - pathology and intervention (iii) Image-based diagnosis and imaging quality assurance. The work will be directed by the needs of industrial and clinical Beneficiaries and Partners, providing a truly multi-disciplinary, multi-sectoral environment for the ESRs. This will combine the expertise of nine core Beneficiaries (5 academic, 4 industrial) and 10 Partners (5 clinical, 4 industrial, 1 academic) to provide scientific support, secondments and training. VPH-CaSE will foster the development of ESRs within a collaborative environment. The recruited researchers will find themselves in an enviable position to leverage the expertise of a strategic sector of the European medical devices/simulation industry and engage with the issues faced by clinical experts in the domain of cardiac medicine and cardiovascular support. Their postgraduate studies will be informed by a translational bias that delivers a competitive skill-set, equipping them to address the challenges presented by a career at the cutting edge of technological innovation in healthcare delivery. The inclusion of a technology translation SME within the consortium is designed to promote the delivery of novel, tangible research outputs, providing benefits to a breadth of European sectors (eg. biomedical, clinical, VPH). The ultimate vision is the production of VPH-capable scientists with experience of tight integration of academic/industrial/clinical areas, able to apply their skills to real life scenarios, accelerating the acceptance of innovative and effective healthcare in the clinic.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ? | |
| Ansys France SAS | 262.876 € |
| Centre National de la Recherche Scientifique Cnrs | 525.751 € |
| Leeds Test Objects Ltd. | 273.288 € |
| 255.374 € | |
| Politecnico DI Milano | 516.123 € |
| Technische Universiteit Eindhoven | 510.749 € |
| 546.576 € | |
| Therenva | 262.876 € |
| University College London | 546.576 € |
Quelle: https://cordis.europa.eu/project/id/642612
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: C.H.U. de Rennesntchaillou, Rennes Cedex, Frankreich.
Die Visualisierungen zu "Centre Hospitalier Universitaire de Rennes - EU-Förderung (3.700.187 €): VPH-Kardiovaskuläre Simulation und Experimente für personalisierte Medizinprodukte"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
